

There is increasing evidence to include combined neoadjuvant chemoradiotherapy (CRT) as an alternative to surgical resection alone, to improve survival for locoregional oesophageal cancer. More recently, attention has focused on the presence of extracapsular lymph node involvement (LNI), which identifies a subgroup of patients with significantly worse long-term survival. Little is known about the effects of neoadjuvant chemoradiotherapy (CRT) on the presence of extracapsular LNI and its prognostic value in patients with resected oesophageal cancer.
A research article to be published in April 28, 2010 in the World Journal of Gastroenterology addresses this question. The research team, led by Dr Metzger R and Dr Hoelscher AH from the Department of General, Visceral, and Cancer Surgery, Centre for Integrated Oncology, University of Cologne, Germany investigated the effects of neoadjuvant CRT on the presence of extracapsular LNI and its prognostic value in patients with resected oesophageal cancer. Two hundred and ninety-eight patients with advanced oesophageal cancer underwent esophagectomy, of whom 68.8% were treated with neoadjuvant CRT prior to resection. A total of 986 metastatic LNs were examined.
The results support the hypothesis that extracapsular LNI is not influenced by neoadjuvant CRT and identifies a subgroup of oesophageal cancer patients with a significantly worse long-term survival. Therefore extracapsular LNI should be noted as a negative prognostic factor and should be taken into account for a revised staging system for oesophageal cancer.
Cardiac patients trial home-based rehabilitation
Health undervalued in reproductive rights debate
Decision support service offers assistance in diagnosing paediatric mental health issues
Researchers clone key sperm-binding proteins